Cellectis Valuation
| ALCLS Stock | EUR 1.73 0.02 1.17% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Cellectis shows a prevailing Real Value of €1.81 per share. The current price of the firm is €1.73. Our model approximates the value of Cellectis from analyzing the firm fundamentals such as Shares Outstanding of 55.59 M, operating margin of (6.01) %, and Return On Equity of -0.56 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Cellectis' price fluctuation is relatively risky at this time. Calculation of the real value of Cellectis is based on 3 months time horizon. Increasing Cellectis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cellectis' intrinsic value may or may not be the same as its current market price of 1.73, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.73 | Real 1.81 | Hype 1.73 | Naive 1.75 |
The intrinsic value of Cellectis' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cellectis' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cellectis helps investors to forecast how Cellectis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cellectis more accurately as focusing exclusively on Cellectis' fundamentals will not take into account other important factors: Cellectis Total Value Analysis
Cellectis is presently projected to have takeover price of 78.42 M with market capitalization of 118.4 M, debt of 91.56 M, and cash on hands of 47.91 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cellectis fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
78.42 M | 118.4 M | 91.56 M | 47.91 M |
Cellectis Investor Information
About 21.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cellectis recorded a loss per share of 2.13. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 1st of November 2011. Based on the key indicators related to Cellectis' liquidity, profitability, solvency, and operating efficiency, Cellectis is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Cellectis Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cellectis has an asset utilization ratio of 15.0 percent. This connotes that the Company is making €0.15 for each dollar of assets. An increasing asset utilization means that Cellectis is more efficient with each dollar of assets it utilizes for everyday operations.Cellectis Ownership Allocation
Cellectis holds a total of 55.59 Million outstanding shares. Almost 78.75 percent of Cellectis outstanding shares are held by general public with 21.25 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cellectis Profitability Analysis
The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M.About Cellectis Valuation
The stock valuation mechanism determines Cellectis' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cellectis based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cellectis. We calculate exposure to Cellectis's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cellectis's related companies.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. CELLECTIS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 161 people.
8 Steps to conduct Cellectis' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cellectis' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cellectis' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cellectis' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cellectis' revenue streams: Identify Cellectis' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cellectis' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cellectis' growth potential: Evaluate Cellectis' management, business model, and growth potential.
- Determine Cellectis' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cellectis' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.